With the advent of electronic health records, it is now easier than ever to keep up with what medications a patient is actually taking, and (especially in the arena of glaucoma) the several classes of medications, such as steroids, beta blockers, and antihistamines, that can influence how patients’ eyes behave. With this in mind, I had a patient come in the other day with an interesting question regarding her intraocular pressure (IOP).
It’s been a busy week for ophthalmology research and news after both the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle and the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans.
Results from a series of preclinical studies are providing proof of principle that gene targeting using CRISPR-Cas9 genome-editing technology can prevent or treat glaucoma associated with mutations in the myocilin (MYOC) gene.
IOL implantation was associated with more inflammation and slightly more visual obscuration in 120 children age 2 or younger undergoing bilateral cataract surgery. However, the rate of glaucoma was similar compared with an aphakic group.
Treating and managing chronic glaucoma can be rewarding as an optometrist. The frequency of office visits to monitor this chronic disease provides ODs an opportunity to develop a close relationship with their patients while providing medical eye care.
Although the diagnosis of primary congenital or early developmental glaucoma is often straightforward, similar phenotypic features can occur in other paediatric conditions, which are consequently sometimes mistaken for early childhood glaucoma. Ophthalmologists who care for children with glaucoma must keep such potential mimics in mind.